Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Windtree Therapeutics Inc (WINT)

Windtree Therapeutics Inc (WINT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 355
  • Shares Outstanding, K 592
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,290 K
  • EBIT $ -26 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.10
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -58.94
  • Most Recent Earnings $-20.91 on 08/19/24
  • Next Earnings Date 11/14/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -2.27
  • Number of Estimates 1
  • High Estimate -2.27
  • Low Estimate -2.27
  • Prior Year -15.47
  • Growth Rate Est. (year over year) +85.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5300 +6.21%
on 11/08/24
1.2000 -53.09%
on 10/21/24
-0.1521 (-21.27%)
since 10/11/24
3-Month
0.5300 +6.21%
on 11/08/24
13.2400 -95.75%
on 08/20/24
-11.2371 (-95.23%)
since 08/12/24
52-Week
0.5300 +6.21%
on 11/08/24
22.3614 -97.48%
on 11/30/23
-17.4101 (-96.87%)
since 11/10/23

Most Recent Stories

More News
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong

WINT : 0.5629 (-6.18%)
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3

WINT : 0.5629 (-6.18%)
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

WINT : 0.5629 (-6.18%)
Windtree To Present at the ThinkEquity Conference on October 30th

WINT : 0.5629 (-6.18%)
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

WINT : 0.5629 (-6.18%)
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design

WINT : 0.5629 (-6.18%)
Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure

Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders.

WINT : 0.5629 (-6.18%)
Pre-Market Brief: Stocks Mixed as Bond Yields Rebound

December S&P 500 futures (ESZ22) are trending lower -1.15% this morning, erasing yesterday’s gains after three major US benchmark indices bounced back sharply during the regular session as risk appetite...

ESZ22 : 3,871.47s (-0.66%)
HMB.S.DX : 158.100 (+0.96%)
WINT : 0.5629 (-6.18%)
AMPS : 3.11 (-9.06%)
FSLR : 182.26 (-5.97%)
SUNL : 0.2200 (unch)
CNXA : 1.5000 (+38.89%)
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE)...

WINT : 0.5629 (-6.18%)
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better...

WINT : 0.5629 (-6.18%)

Business Summary

Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. The company's proprietary technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous...

See More

Key Turning Points

3rd Resistance Point 0.6661
2nd Resistance Point 0.6430
1st Resistance Point 0.6030
Last Price 0.5629
1st Support Level 0.5399
2nd Support Level 0.5168
3rd Support Level 0.4768

See More

52-Week High 22.3614
Fibonacci 61.8% 14.0218
Fibonacci 50% 11.4457
Fibonacci 38.2% 8.8696
Last Price 0.5629
52-Week Low 0.5300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar